AI-generated analysis. Always verify with the original filing.
MetaVia Inc. announced financial results for the year ended December 31, 2025, reporting net loss of $13.0 million or $7.35 per share, R&D expenses of $6.8 million, G&A expenses of $6.9 million, and cash of $10.3 million. The company highlighted positive Phase 1 data for DA-1726 showing 9.1% weight loss and upcoming Phase 1 Part 3 study initiation in April 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated March 26, 2026. 104 Cover Page
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $6.80 | GAAP |
| General and Administrative Expenses | $6.90 | GAAP |
| Total Operating Expenses | $13.70 | GAAP |
| Total Other Income | $0.70 | GAAP |
| Net Loss | $13.00 | GAAP |
| Net Loss per Basic and Diluted Share | $7.35 | GAAP |